Related Experiment Video
Updated: Feb 24, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
A Case of Fulminant Meningococcemia: It Is All in the Complement
Kellie L Hawkins1,2, Mariah Hoffman2,3, Sonia Okuyama2,4
1Division of Infectious Disease, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Abstract:
Eculizumab is a novel monoclonal antibody that inhibits complement-mediated hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH). Complement deficiency is a well-known risk factor for meningococcal infection. We describe a case of a young patient with PNH treated with eculizumab who presented with a life-threatening case of nongroupable meningococcemia. As this new biologic agent becomes more widely prescribed, providers should be aware of the increased risk of meningococcemia. In addition to vaccination, providers may consider the use of oral penicillin for antibiotic prophylaxis against Neisseria meningitidis in these cases of functional complement deficiency.
Related Concept Videos
Complement System
Acute Pyelonephritis II: Diagnostic Studies and Management
Pneumonia III: Complications and Assessment
Pneumonia II: Pathophysiology

